Home
Risk Evaluation and Mitigation Strategies (REMS) Compliance Program
U.S. Food and Drug Administration
22 ม.ค. 2021
การดู 13,419 ครั้ง
OTC Monograph Reform in the CARES Act: Safety Orders
Navigating the World of Combination Products (2of15) REdI – May 29-30, 2019
New Approaches for an Integrated Nonclinical-Clinical QT/Proarrhythmic Risk Assessment (2 of 2)
Advancing Transparency and Regulatory Science Activities on Risk Evaluation and Mitigation Strategy
71st Meeting of the Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC)
4th Annual National Black Family Cancer Awareness, Engaging the Generations, #BlackFamCan
Contact Lenses: Safe Use of Hydrogen Peroxide Solution #shorts
Compounding: Cleanrooms and Cleanroom Behaviors: Why they Matter
CDER BIMO GCP Compliance and Enforcement
REMS (February 2015)
New Approaches for an Integrated Nonclinical-Clinical QT/Proarrhythmic Risk Assessment (1 of 2)
Diversity in Clinical Trials: Learn about Enrollment Trends and Resources from FDA
Benefit-Risk Considerations During Drug Product Development (8of14) REdI 2018
Contact Lenses: Safe Use of Hydrogen Peroxide Solution
CMC - NDA requirements and Common Pitfalls of BLAs (14of15) REdI – May 29-30, 2019
Episode 5 - On The Road with Jim Jones - April 2024
Establishment Registration– DRLS Workshop 2020
Strategies to Increase Clinical Trial Participation for Diverse Communities: OMHHE REACH Consortium
Chemistry, Manufacturing, and Controls (CMC) for an IND (7of14) REdI 2018
FDA D.I.S.C.O. Burst Edition: FDA approval of Ojemda (tovorafenib) for relapsed or refractory ped...